Type Segment Analysis: Genetic Testing (Largest & Fastest-Growing Segment)

The genetic testing segment dominated the solid tumor testing market, accounting for 63.65% of the market share in 2026, while also emerging as the fastest-growing segment. Its leadership is driven by the increasing adoption of precision oncology, where genetic profiling enables clinicians to identify tumor-specific mutations and select targeted treatment strategies. The growing integration of molecular diagnostics into routine cancer care, rising demand for personalized therapies, and continuous advancements in sequencing technologies have strengthened the role of genetic testing in clinical decision-making. As healthcare providers place greater emphasis on early detection, treatment optimization, and ongoing disease monitoring, genetic testing is expected to maintain both its dominant market position and robust growth momentum.

End Use Segment Analysis: Hospitals (Largest Segment) vs Diagnostic Laboratories (Fastest-Growing Segment)

Hospitals accounted for the largest share of 37.8% in 2026 in the end-use segment. Their leadership is supported by the availability of multidisciplinary oncology teams, advanced diagnostic infrastructure, and integrated patient care pathways that enable comprehensive cancer diagnosis and treatment within a single healthcare setting. The increasing number of cancer diagnoses and growing adoption of precision medicine continue to strengthen hospitals' position as the primary providers of solid tumor testing services.

The diagnostic laboratories segment is expected to record the fastest growth in the solid tumor testing market as demand rises for specialized molecular testing and high-throughput diagnostic services. Continuous improvements in laboratory automation, expanding access to advanced genomic technologies, and increasing referrals from healthcare providers are contributing to greater testing volumes. The ability of diagnostic laboratories to deliver accurate and timely results while supporting personalized treatment decisions is expected to accelerate segment expansion.

Application Segment Analysis: Breast Cancer (Largest Segment) vs Lung Cancer (Fastest-Growing Segment)

The breast cancer application segment held the largest share of 27.97% in 2026. Its leading position is driven by the high utilization of molecular and genetic testing for diagnosis, treatment selection, and disease monitoring. Increasing awareness of early cancer detection, broader implementation of personalized treatment approaches, and continued adoption of biomarker-based testing have reinforced the importance of breast cancer diagnostics across healthcare systems.

The lung cancer application segment is anticipated to grow at the fastest pace owing to the increasing use of comprehensive biomarker testing to guide targeted therapies and immunotherapy selection. Advancements in molecular diagnostics, expanding availability of precision oncology solutions, and growing emphasis on identifying actionable genetic alterations are encouraging wider adoption of solid tumor testing for lung cancer, supporting sustained growth throughout the forecast period.